These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 16361013)

  • 1. Neuromuscular disorders: orphan diseases deserve attention.
    de Visser M
    Lancet Neurol; 2006 Jan; 5(1):13-4. PubMed ID: 16361013
    [No Abstract]   [Full Text] [Related]  

  • 2. Crafting a robust business model for orphan drug development.
    Philippidis A
    Hum Gene Ther; 2011 Jul; 22(7):781-3. PubMed ID: 21756074
    [No Abstract]   [Full Text] [Related]  

  • 3. Drug labels: a flawed source of data for studying orphan drug approvals.
    Kesselheim AS; Avorn J
    Clin Pharmacol Ther; 2012 Dec; 92(6):694; author reply 695. PubMed ID: 23073207
    [No Abstract]   [Full Text] [Related]  

  • 4. A new toolkit for conducting clinical trials in rare disorders: will this dog hunt?
    Peterson RG; Macleod SM; Klein AV
    J Popul Ther Clin Pharmacol; 2014; 21(1):e79-80. PubMed ID: 24671905
    [No Abstract]   [Full Text] [Related]  

  • 5. The study of drugs for rare disorders: harnessing research contributions by Canadian academic institutions.
    Macleod S; Lasko P; Mackenzie A
    J Popul Ther Clin Pharmacol; 2014; 21(1):e47-55. PubMed ID: 24671865
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Orphan drugs: Indian perspective.
    Kumar H; Sarma P; Medhi B
    Indian J Pharmacol; 2017; 49(4):267-269. PubMed ID: 29326485
    [No Abstract]   [Full Text] [Related]  

  • 7. The role of academic institutions in the development of drugs for rare and neglected diseases.
    Coles LD; Cloyd JC
    Clin Pharmacol Ther; 2012 Aug; 92(2):193-202. PubMed ID: 22760003
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ethical, legal and social implications of rare diseases and orphan drugs in Europe: meeting report of a Brocher symposium.
    Picavet E; Cassiman D; Pinxten W; Simoens S
    Expert Rev Pharmacoecon Outcomes Res; 2013 Oct; 13(5):571-3. PubMed ID: 24138643
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Challenges and Hurdles to Business as Usual in Drug Development for Treatment of Rare Diseases.
    Swinney DC
    Clin Pharmacol Ther; 2016 Oct; 100(4):339-41. PubMed ID: 27393380
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Raising orphans: how clinical development programs of drugs for rare and common diseases are different.
    Orfali M; Feldman L; Bhattacharjee V; Harkins P; Kadam S; Lo C; Ravi M; Shringarpure DT; Mardekian J; Cassino C; Coté T
    Clin Pharmacol Ther; 2012 Aug; 92(2):262-4. PubMed ID: 22739137
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Law and research could add up to profitable niche drugs.
    Haefner B
    Nature; 2007 Apr; 446(7138):856. PubMed ID: 17443162
    [No Abstract]   [Full Text] [Related]  

  • 12. Trends from two decades of orphan designations in paediatric rare neuromuscular diseases.
    Duarte DM; da Silva Lima MB; Sepodes B
    J Neurol Sci; 2024 May; 460():122989. PubMed ID: 38581740
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Do we need authorized orphan drugs when compounded medications are available?
    Dooms M; Pincé H; Simoens S
    J Clin Pharm Ther; 2013 Feb; 38(1):1-2. PubMed ID: 22973866
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Flexibility in the FDA approach to orphan drug development.
    Hunter NL; Rao GR; Sherman RE
    Nat Rev Drug Discov; 2017 Nov; 16(11):737-738. PubMed ID: 28860647
    [No Abstract]   [Full Text] [Related]  

  • 15. A new toolkit for conducting clinical trials in rare disorders.
    Abrahamyan L; Diamond IR; Johnson SR; Feldman BM
    J Popul Ther Clin Pharmacol; 2014; 21(1):e66-78. PubMed ID: 24671886
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Defining orphan conditions in the context of the European orphan regulation: challenges and evolution.
    O'Connor DJ; Sheean ME; Hofer MP; Tsigkos S; Mariz S; Fregonese L; Larsson K; Hivert V; Westermark K; Naumann-Winter F; Stoyanova-Beninska V; Barišić I; Capovilla G; Magrelli A; Sepodes B
    Nat Rev Drug Discov; 2019 Jul; 18(7):479-480. PubMed ID: 30940922
    [No Abstract]   [Full Text] [Related]  

  • 17. Rare lung disease and orphan drug development.
    Spagnolo P; du Bois RM; Cottin V
    Lancet Respir Med; 2013 Aug; 1(6):479-87. PubMed ID: 24429246
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Proposed 'grant-and-access' program with price caps could stimulate development of drugs for very rare diseases.
    Valverde AM; Reed SD; Schulman KA
    Health Aff (Millwood); 2012 Nov; 31(11):2528-35. PubMed ID: 23129684
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The design and development of therapeutic agents for neuromuscular diseases.
    Lewis NJ
    Prog Clin Biol Res; 1985; 197():105-10. PubMed ID: 4070284
    [No Abstract]   [Full Text] [Related]  

  • 20. [Orphan drugs. Drugs for treatment of rare diseases].
    Hennemann A
    Med Monatsschr Pharm; 2004 Aug; 27(8):256-9. PubMed ID: 15382448
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.